

## DAFTAR PUSTAKA

- Arifin, M. R. A. 2011. Hubungan Antara Hiperglikemia dan Mortalitas Pada Anak Dengan Sepsis di Ruang Rawat Inap Intensif RSUD Dr . Moewardi Surakarta. *Jurnal Kedokteran Indonesia*. 2 (1): 34–38.
- Bergogne-Berezin, Eugene., Herman Friedman., Mauro Bendinelli. 2008. *Acinetobacter Biology and Pathogenesis*. Springer Science. New York, USA.
- bioMerieux. 2012. Antimicrobial Susceptibility Testing, 1–6. France
- Bollenbach, Tobias. 2015. Antimicrobial interactions: mechanism and implication for drug discovery and resistance evolution. *Science Direct*. Vol: 27: 1-9.
- Bonomo, R. A., Dora Szabo. 2006. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin.Infect.Dis.*, 43 Suppl 2: 1537–6591; S49–S56. America.
- Brunton, Laurence., Keith Parker., Donald Blumenthal., Iain Buston. 2008. Goodman's and Gilman's Manual of Pharmacology and Therapeutics, Mc Graw-Hill, USA.
- Burgess, D. S., Carden, M. F., Nathisuwan, S., Suntanirand, P., & Malathum, K. 2007. In Vitro Activity of Colistin ( COL ) against Multi-Drug Resistant ( MDR ) *Acinetobacter baumannii* ( ACN ). ICAAC, Chicago.
- Byarugaba, D., Amábile-Cuevas, C. F. 2010. Mechanism of Antimicrobial Resistance. Springer Science. *Antimicrobial Resistance in Developing Countries*. Department of Veterinary Microbiology and Parasitology, Makerere University, Kampala Uganda. 2: 15–26.
- Carlier, M., Carrette, S., Roberts, J. A., Stove, V., Verstraete, A., Hoste, E., *et al*. 2013. Meropenem and piperacillin / tazobactam prescribing in critically ill patients : does augmented renal clearance affect pharmacokinetic / pharmacodynamic target attainment when extended infusions are used ? *Critical Care*, 17(3), R84. Belgium.
- Chan J Z-M., Mihail R H., Nicholas J L., Chrystala C., Mark J Pallen. 2012. Defining bacterial species in the genomic era: insights from the genus *Acinetobacter*. *BMC Microbiology*. 12:302.
- Ciptaningtyas, V.R. 2014. Antibiotik untuk Mahasiswa Kedokteran. Graha Ilmu. Yogyakarta.
- Cosgrove, S E., Edina Avdic., Kate Dzintars., Janessa S. 2014. *Antibiotic Guidelines 2015-2016*:. Johns Hopkins Medicine: 110–124. Amerika
- Dellinger, R., Levy, M., Rhodes, A., Djillali A., Herwig G., Steven M O., *et al*. 2013. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *CCM Journal*. 41(2): 580–637.

- Dewi, R. 2010. Sepsis pada Anak : Pola Kuman dan Uji Kepekaan. Majalah Kedokteran Indonesia. Vol: 61: 101–106. Jakarta.
- DiPiro, Joseph T., et.all. 2005. Pharmacotherapy (A Pathophysiology Approach), 6<sup>th</sup> ed., Mc Graw-Hill, USA.
- Doughari, H. J., Ndakidemi, P. A., Human, I. S., Benade, S. 2011. Virulence factors and antibiotic susceptibility among verotoxic non O157: H7 Escherichia coli isolates obtained from water and wastewater samples in Cape Town, South Africa. *African Journal of Biotechnology*, 10(64), 14160–14168. Africa.
- Doughari, Hamuel J., Patrick Alois Ndakidemi., Izanne Susan Human., Spinney Benade. 2011. The ecology, biology, and pathogenesis of Acinetobacter spp.: an overview, Microbes and Environment, Applied Sciences Faculty, Cape Peninsula University of Technology, South Africa.
- ETEST ® Reading Guide Aerobic Bacteria ETEST ® Reading Guide Antifungals, 6, 7–8.
- FDA. (2005). Zosyn®. Wyeth, 1–24. Philadelphia
- Fishbain, J., Peleg, A. Y. 2010. Treatment of *Acinetobacter* Infections. *Clinical Infectious Diseases*, 51(1): 79–84. America.
- Gunnison, J. B., Kunishige, E., Coleman, V. R., Jawetz, E. 1955. The mode of action of antibiotic synergism and antagonism: the effect in vitro on bacteria not actively multiplying. *Journal of General Microbiology*, 13(3): 509–518. USA
- Guntur, H. A. 2008. SIRS, SEPSIS dan SYOK SEPTIK (Imunologi, Diagnosis dan Penatalaksanaan). Surakarta: Sebelas Maret University Press.
- Harris, P., Peleg, A. Y., Iredell, J., Ingram, P. R., Miyakis, S., Stewardson, A. J., et al. 2015. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. *Trials*. 16(1), 24: 1-8
- Henwood, C. J., Gatward, T., Warner, M., James, D., Stockdale, M. W., Spence, R. P., et al. 2002. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). *The Journal of Antimicrobial Chemotherapy*, 49(3): 479–487. UK.
- Howland, Richard D., Mycek, Mary J. 2006. Pharmacology 3<sup>rd</sup> ed. Lippicott's illustrated reviews. Gopsons Paper Ltd. India.
- Hu, Z. Q., Zhao, W. H., Yoda, Y., Asano, N., Hara, Y., Shimamura, T. 2002. Additive, indifferent and antagonistic effects in combinations of epigallocatechin gallate with 12 non-β-lactam antibiotics against methicillin-resistance Staphylococcus aureus. *Journal of Antimicrobial Chemotherapy*, 50(6): 1051–1054. Japan.

- Igbinsa, E. O., Odjadjare, E. E., Igbinsa, I. H., Orhue, P. O., Omoigberale, M. N. O., Amhanre, N. I. 2012. Antibiotic Synergy Interaction against Multidrug-Resistant *Pseudomonas aeruginosa* Isolated from an Abattoir Effluent Environment. *The Scientific World Journal*. 1-5
- Jain, S. N., Vishwanatha, T., Reena, V., Divyashree, B. C., Sampath, A., Siddhalingeswara, K. G., Ramesh, I. 2011. Antibiotic Synergy Test: Checkerboard Method on Multidrug Resistant *Pseudomonas aeruginosa*. *International Research Journal of Pharmacy*, 2(12): 196–198. India.
- Jenkins, S. G., Schuetz, A. N. 2012. Current concepts in laboratory testing to guide antimicrobial therapy. *Mayo Clinic Proceedings*, 87(3): 290–308. New York.
- Joly-Guillou, Marie-Laure., Kempf, M., Cavallo, J.-D., Chomarat, M., Dubreuil, L., Maugein, J., *et al.* 2010. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. *BMC Infectious Diseases*, 10, 72: 1-9. New York.
- Joyce, L. F., Downes, J., Stockman, K., Andrew, J. H. 1992. Comparison of five methods, including the PDM Epsilometer test (E test), for antimicrobial susceptibility testing of *Pseudomonas aeruginosa*. *Journal of Clinical Microbiology*, 30(10): 2709–2713. Australia.
- Juniatiningsih, A., Aminullah, A., Firmansyah, A. 2008. Profil Mikroorganisme Penyebab Sepsis Neonatorum di Departemen Ilmu Kesehatan Anak Rumah Sakit Cipto Mangunkusumo Jakarta, vol: 10 (1): 60-65
- Kache, S., Schroeder, A., Trinkus, P. 2015. Sepsis. *Pediatrics* *Staford School of Medicine*. 1–13. America.
- Karah, N., Haldorsen, B., Hegstad, K., Simonsen, G. S., Sundsfjord, A., Samuelsen, Ø. 2011. Species identification and molecular characterization of *Acinetobacter* spp. blood culture isolates from Norway. *The Journal of Antimicrobial Chemotherapy*, 66(4): 738–744. Norwegia.
- Katzung, B.G. 2004. *Basic and Clinical* . 9<sup>th</sup> ed. Lange Medical Books. New York.
- Kherallah, Mazen. 2016. *Combination Antibiotics*. King Faisal Specialist Hospital and Research Center. USA.
- Li, C., Du, X., Kuti, J. L., Nicolau, D. P. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. *Antimicrobial Agents and Chemotherapy*, 51(5): 1725–1730. America.
- Liofilchem. 2015. *MIC Test Strip Preliminary Guide*: 1–20.
- Lister, P. D., Prevan, a M., Sanders, C. C. 1997. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. *Antimicrobial Agents and Chemotherapy*, vol: 41(4): 721–727. America.

- Long, Sarah S., Pickering, Larry K., Prober, C. G. 2012. Principle and Practice of Pediatric Infectious Disease, 4<sup>th</sup> ed. Elsevier. Australia
- Maragakis, Lisa L., Perl, T. M. 2008. *Acinetobacter baumannii*: Epidemiology, Antimicrobial Resistance, and Treatment Options. *Clinical Infectious Diseases*, Oxford Journal. Vol: 46 (8): 1254–1263. America.
- Mattoes, Holly M., Kuti, Joseph L., Drusano, George L., Nicolau, D. P. 2004. Optimizing antimicrobial pharmacodynamics: Dosage strategies for meropenem. *Clinical Therapeutics*. Vol: 26 (8): 1187–1198. New York.
- MIC test strip preliminary guide. 2010. Via Scozia. Italy.
- Mishra, Asit., Sudhir Mishra., Geetha J., Raj K M., Gupta, P. K., Patra, D. P. 1998. *Acinetobacter* Sepsis in newborns. *Indian Pediatrics*. 35 (JANUARY): 27–32. India
- Montero, A., Ariza, J., Corbella, X., Doménech, A., Cabellos, C., Ayats, J., *et al.* 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant *Acinetobacter baumannii* in a mouse pneumonia model. *Journal of Antimicrobial Chemotherapy*. Vol: 54 (6): 1085–1091. Spain.
- Moody, J. A., Peterson, L. R., Gerding, D. N. 1984. In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics. *Antimicrobial Agents and Chemotherapy*. Vol: 26 (2): 256–259. America.
- Mortensen, Brittany L., Skaar, Eric P. 2012. Host-microbe interactions that shape the pathogenesis of *Acinetobacter baumannii* infection. *Cellular Microbiology*. Vol: 14 (9): 1336–1344. USA.
- Moulds, Robert., Rao, G., Tevita, Sukafa., Waqanibete., Tikoduadua., Tupou Wata., *et al.* 2011. Antibiotic Guidelines. 3<sup>rd</sup> ed. National Drugs and Therapeutics Subcommittee: 1–19. Ministry of Health Government of Fiji. Japan.
- Napitupulu, Herald H. 2010. Sepsis. *Anesthesia & Critical Care*. Vol: 28 (3): 50–58. Indonesia.
- Nichols, G.David., Lippincott wiliams&wilkin. 2008. *Rogers' textbook of pediatric intensive care*. 4<sup>th</sup> ed. USA.
- Nicolau, David P. 2008. Pharmacokinetic and Pharmacodynamic Properties of Meropenem, *Clinical Infectious Disease*. Oxford journals. 6102(Suppl 1): S32-S40. America.
- Orhan, G., Bayram, A., Zer, Yasemin., Balci, Iclal. 2005. Synergy tests by E test and checkerboard methods of antimicrobial combinations against *Brucella melitensis*. *Journal of Clinical Microbiology*. Vol: 43 (1): 140–143. America.

- Peleg, A. Y., Seifert, H., Paterson, D. L. 2008. *Acinetobacter baumannii*: Emergence of a successful pathogen. *Clinical Microbiology Reviews*. Vol: 21 (3): 538–582. America.
- Pradipta IS., 2009. Antibiotic Use Evaluation at Ward of Internal Medicine dr. Sardjito Hospital November – December 2008 [Thesis]. Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia.
- Pradipta, Ivan S., Sandiana, A. T., Halimah, E., Diantini, A., Lestari, K., Abdulah, R. 2013. Microbial and resistance profile in isolate from adult sepsis patients: An observational study at an Indonesian private hospital during 2009-2012. *International Journal of Pharmaceutical Sciences Review and Research*. Vol: 19 (2): 24–29. Singapore.
- R. Nugroho, Bayu Aji. 2012. Hubungan Faktor Risiko Terjadinya *Acinetobacter* sp MDRO terhadap Kematian Penderita Sepsis di PICU Rumah Sakit dr. Kariadi Semarang. Universitas Diponegoro. Semarang.
- Rizki, Ludhang P. 2015. Studi efek kombinasi meropenem, gentamisin, dan levofloksasin terhadap isolat klinik multidrug resistant *Pseudomonas aeruginosa* (MDR-PA) dengan metode e-test. Universitas Gadjah Mada, Indonesia.
- Safdar, N., Handelsman, J., Maki, D. G. 2004. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. *The Lancet Infectious Disease*. Vol: 4: 519–527. USA.
- Smaill, Fiona. 2000. Antibiotic susceptibility and resistance testing: An overview. *Canadian Journal of Gastroenterology*. Vol: 14 (10): 871–875. Ontario.
- Starr, Marlene E., Saito, Hiroshi. 2014. Sepsis in Old Age: Review of Human and Animal Studies. *Aging and Disease*. Vol: 5 (2): 126-136. University of Kentucky. USA.
- Stearns-Kurosawa, Deborah J., Osuchowski, M. F., Valentine, C., Kurosawa, S., Remick, D. G. 2011. The pathogenesis of sepsis. National Institute of Health. Vol: 6: 19–48. America.
- Su, Siou Cing., Mario Vaneechoutte., Lenie Dijkshoorn., Yu Fang Wei., Ya Lei Chen., Tsung Chain Chang. 2009. Identification of Non-Fermenting Gram-negative Bacteria of Clinical Importance by an Oligonucleotide Array. *Journal of Medical Microbiology*. Britain.
- Sueke, Henri., Kaye, Stephen B., Neal, Timothy., Hall, A., Tuft, Stephen., Parry, C. M. 2010. An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis. *Investigative Ophthalmology and Visual Science*. Vol: 51 (8): 4151–4155. UK.
- Tambajong, Rheza N., Lalenoh, Diana C., Kumaat, L. 2015. Profil Penderita Sepsis di ICU RSUP Prof . Dr . R . D . Kandou Manado Periode Desember 2014- November 2015. Universitas Sam Ratulangi, Manado.

- Tamma, Pranita D., Cosgrove, Sara E., Maragakis, Lisa L. 2012. Combination therapy for treatment of infections with gram-negative bacteria. *Clinical Microbiology Reviews*. Vol: 25 (3): 450–470. USA
- Towner, K. J. 1997. Clinical importance and antibiotic resistance of Acinetobacter spp. *Journal of Medical Microbiology*. Vol: 46: 721–746. Nottingham.
- Van belkum, Alex., Halimi, Diane., Bonetti, Eve-Julie., Renzi, G., Cherkaoui, A., Sauvonnet, V., *et al.* 2014. Meropenem/colistin synergy testing for multidrug-resistant Acinetobacter baumannii strains by a two-dimensional gradient technique applicable in routine microbiology. *Journal of Antimicrobial Chemotherapy*. Vol: 70 (1): 167–172. USA.
- Viswanathan, Rajlakshmi., Singh, Arun K., Basu, S., Chatterjee, S., Roy, S., Isaacs, D. 2014. Multi-drug-resistant, non-fermenting, gram-negative bacilli in neonatal sepsis in Kolkata, India: a 4-year study. *Paediatrics and International Child Health*. Vol: 34 (1): 56–9. Australia.
- Watson, R. Scott., Carcillo J. A., Linde-Zwirble, W. T., Clermont, G., Lidicker, Jeffrey., Angus, D. C. 2003. The Epidemiology of Severe Sepsis in Children in the United States. *American Journal of Respiratory and Critical Care Medicine*. Vol: 167: 695-701. USA.
- White, Roger L., Burgess, David S., Manduru, M., Bosso, John A. 1996. Comparison of three different in vitro methods of detecting synergy : time-kill , checkerboard , and E test . *Antimicrobial Agent and Chemotherapy*. Vol: 40 (8): 1914–1918. America.
- Weber, Marlin., Said, Mardjanis., Kartasasmita, Cissy B., Kusbiyantoro. 2010. Pneumonia Balita. *Buletin Jendela Epidemiologi*: 2087-1546. Kementrian Kesehatan Indonesia. Jakarta.
- Young, Paul. 2013. *Intensive Care Unit Drug Manual*, 2<sup>nd</sup> ed. Wellington Regional Hospital, New Zealand.
- Zhanel, George G., Simor, Andrew E., Vercaigne, Lavern., Mandell, L. 1998. Imipenem and meropenem : Comparison of in vitro activity , pharmacokinetics , clinical trials and adverse effects. *Canadian Journal of Infectious Disease*. Vol: 9 (4): 215–228. America.